Inflammatory Diseases Treatment Market
Number of pages: 100 | Report Format: PDF | Published date: May 22, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
CAGR |
9.5% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Disease Indication, Treatment, End User, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global inflammatory diseases treatment market is expected to register a revenue CAGR of 9.5% during the forecasted period.
Inflammatory Diseases Treatment Market Fundamentals
Inflammatory diseases are defined by continuous inflammation in various body parts. These diseases might have significant health consequences, impacting many organs and systems. The frequency of inflammatory illnesses has noticeably increased in recent years, posing a serious threat to public health globally. A mix of genetic predisposition and environmental variables make up the multifactorial, complicated etiology of inflammatory disorders. Genetic susceptibility is important in some cases because some people may be more likely to have certain diseases than others. The inflammatory response, however, can also be brought on or made worse by environmental factors, including infections, nutrition, lifestyle decisions, and exposure to toxins.
Several factors contribute to the increased incidence of inflammatory disorders. Better diagnosis methods and more understanding among medical professionals have helped to better identify and report these illnesses. As a result, more instances are being identified and diagnosed, which appears to be increasing prevalence rates. The increased frequency of inflammatory illnesses presents serious difficulties for both people and healthcare institutions. The quality of life can be significantly impacted by these illnesses, which are frequently chronic and can cause pain, disability, and decreased productivity. In addition, long-term medication is frequently necessary to manage inflammatory illnesses, which may be expensive and taxing for patients and healthcare professionals.
The global inflammatory diseases treatment industry analysis report comprehensively analyzes the market, with factors that either aid or impede the market growth, such as its drivers, restraints, and opportunities. The research provides insight into the companies that operate in the inflammatory disease’s treatment market and their efforts to position themselves as key players through expansion strategies and innovations. It also highlights recent developments that contribute to the inflammatory disease’s treatment market growth. The research also analyzes the impact of the COVID-19 pandemic.
This research is valuable for businesses seeking insights into the market, customers, and competition. The research provides special insights into the segmentation, regions, market size & projection, revenue CAGRs, and other important information that may help clients make the right decisions. The report assembles data from market players and professionals across the industrial value chain. The study also incorporates qualitative and quantitative assessments from industry professionals. Secondary research, surveys and interviews, and statistical modeling are all used in our research to estimate market size and projection. Our reports deliver the most reliable market data because of our specialized research methods.
Inflammatory Diseases Treatment Market Dynamics
Leading biologics patents expiring cleared the path for biosimilars to enter the market. Due to the rising demand and quicker approval procedure for biosimilars than for new drugs, several manufacturers have moved their attention to this area. This has grown to be a significant market trend. Adalimumab, infliximab, and etanercept biosimilars are competing against Humira, Remicade, and Enbrel, three biologics with considerable market revenue potential. The FDA has authorized five Humira biosimilars, all of which are anticipated to go on sale in the United States in 2023. Additionally, clinical research has already been started to create biosimilar versions of reference biologics that will soon lose their exclusivity. This is projected to increase demand for inflammatory treatments in the upcoming years.
Technology development is an important development that is becoming increasingly popular in managing chronic diseases. Artificial intelligence (AI) and other cutting-edge technologies are being used to treat chronic illnesses. Medical professionals can observe improvements in early intervention and patient outcomes for patients with heart disease, cancer, and diabetes by using Al. For instance, in February 2022, Boston-based firm Biofourmis released Bioformis Care, a service that offers high-quality remote care to patients with chronic conditions. Biofourmis is a leader in artificial intelligence-driven virtual care and digital medicines. The focus of Biofourmis Care will be on boosting provider adherence to treatment guidelines and identifying patterns of clinical deterioration to enable early interventions.
Inflammatory Diseases Treatment Market Ecosystem
Inflammatory Diseases Treatment Market, by Disease Indication
Inflammatory Diseases Treatment Market, by Treatment
Inflammatory Diseases Treatment Market, by End User
Inflammatory Diseases Treatment Market by Treatment
The biologics market had a ~50% revenue share in 2022, which was the highest revenue share. The primary forces driving the development of this market are the advent of biosimilars, the rising use of monoclonal antibodies, and new product launches. AbbVie released RINVOQ in August 2019 as a janus kinase inhibitor for treating rheumatoid arthritis. The NSAIDs market is anticipated to expand as a result of the rise in inflammatory diseases, growing NSAID consumption, and rising demand for over the counter (OTC) drugs.
Government advice to use NSAIDs as the first line of treatment for pain and inflammation is another factor driving up demand for them. The corticosteroid market is anticipated to rise due to rising COPD prevalence, more research, and potential pipeline candidates.
The market segmentation sections provide the inflammatory diseases treatment market outlook in terms of the demarcation of different consumer groups. Market segmentation is the split of an industry into subgroups depending on characteristics such as disease indication, treatment, end user, and region. Market segmentation data helps organizations understand the preferences and distinctive demands of different customer groups and implement targeted marketing strategies. This data additionally helps in identifying potential inflammatory diseases treatment market demand opportunities.
Inflammatory Diseases Treatment Market by Region
North America is the largest market for inflammatory diseases treatment because of factors like an established healthcare system with many famous companies, significant investment, and a need for more potent and secure medications, among other things. In addition, the high income per capita, increase in doctor visits, product approval, and breakthroughs in research because of high financing are some of the reasons that are boosting the North American market's expansion. For instance, 'Trixeo Aerosphere' for the maintenance therapy of COPD gained EU Approval in December 2020 from AstraZeneca, a major pharmaceutical producer.
The market is anticipated to develop because of the growing rates of asthma and COPD in North American countries. For instance, the AAFA article from September 2022 indicated that there are more than 25 million asthma sufferers in the United States. A March 2022 NIH study also noted that more than 15 million persons in the US suffered from COPD. Similar to how asthma is one of Canada's main public health issues, the study industry is anticipated to increase. More than 2,802,700 instances of asthma were reported in Canada, according to Statistics from Canada released in August 2022. The increasing prevalence of people living with asthma drives up the need for medications to treat their original condition.
Based on the regions, the global inflammatory diseases treatment market is segmented into:
The industry's regional segmentation provides insights into geographic pockets in terms of inflammatory diseases treatment industry trends, market size, share, and growth rate. This information helps organizations assess potential growth opportunities in new regional markets, understand competitive threats, and develop localized sales and expansion strategies. This section also offers deeper insights into the regional and country-level inflammatory diseases treatment market overview.
Key Components of the Report
Inflammatory Diseases Treatment Market Competitive Landscape
The market competitive landscape analysis is performed by gathering and evaluating data about the key competitors, industry trends, and market dynamics. It involves collecting and analyzing data on factors such as products, pricing, geographic reach, customer demographics, marketing tactics, and recent developments. Competitive landscape analysis can help organizations identify present or prospective opportunities and risks in the market.
Inflammatory Diseases Treatment Market Strategic Developments
Reasons To Buy This Report
Key Strengths of Our Report
Target Audience to Benefit from this Report.
Inflammatory diseases are defined by continuous inflammation in various body parts. These diseases might have significant health consequences, impacting many organs and systems.
North America region will have the largest inflammatory diseases treatment market size during the forecast period from 2023 to 2031.
The revenue CAGR in the global inflammatory diseases treatment market is expected to have 9.5% during the forecasted period.
Technological advancement & research, and development are growth opportunities in the global inflammatory diseases treatment market.
Non-Steroid Anti-Inflammatory Drug (NSAID) side effects such as stomach ulcers, allergic reactions, dizziness, stomach discomfort, and other conditions are anticipated to hinder market growth.
The major companies participate in mergers and acquisitions, creating new products, partnerships, collaborations, and growth plans to increase market penetration.
The technology development and leading biologics patents expiring cleared the path for biosimilars are the drivers of the global inflammatory diseases treatment market.
Some key global inflammatory disease market players include AstraZeneca, Eli Lilly and Company, and Merck & Co. Inc.
The biologics segment has the highest global inflammatory diseases treatment market share.
*Insights on financial performance are subject to the availability of information in the public domain